Literature DB >> 21214127

Management of acute partial-thickness bums.

Maria C Kessides1, Maral Kibarian Skelsey.   

Abstract

More than 1 million burns occur annually in the United States. The management of first-degree burns is limited to minor pain control whereas third-degree burns require skin grafting. However, second-degree/partial-thickness burns disrupt the epidermis and part of the dermis, thereby requiring acute wound care, pain control, and infection control. There are many different topical treatments and dressings for acute partial-thickness burns, and the clinical superiority of any one treatment is unclear. Because dermatologists may manage acute outpatient burns, we review the most widely utilized treatments that may be administered on an outpatient basis.

Entities:  

Mesh:

Year:  2010        PMID: 21214127

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  3 in total

1.  Physicians based emergency medical services for the management of burn injuries in trauma centers of the center region of Saudi Arabia: evaluation of physicians' knowledge and experience.

Authors:  Homaidan T Alhomaidan; Zafar Rasheed; Manal M Alsudais; Asma M AlMutairi; Khawlah A Alzaben; Sara M AlMutairi; Lamees I Alissa; Adel M Widyan; Abdullah S Alkhamiss; Sharifa K Alduraibi; Waleed Al Abdulmonem
Journal:  Int J Burns Trauma       Date:  2021-06-15

2.  Long-term quality of life and cost-effectiveness of treatment of partial thickness burns: A randomized controlled trial comparing enzyme alginogel vs silver sulfadiazine (FLAM study).

Authors:  Zjir M Rashaan; Pieta Krijnen; Kelly Aa Kwa; Margriet E van Baar; Roelf S Breederveld; M Elske van den Akker-van Marle
Journal:  Wound Repair Regen       Date:  2020-02-11       Impact factor: 3.617

3.  Recording Patient Data in Burn Unit Logbooks in Rwanda: Who and What Are We Missing?

Authors:  Elizabeth Miranda; Lotta Velin; Faustin Ntirenganya; Robert Riviello; Francoise Mukagaju; Ian Shyaka; Yves Nezerwa; Laura Pompermaier
Journal:  J Burn Care Res       Date:  2021-05-07       Impact factor: 1.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.